Session 36 - 13th CROI

Home

Session 36 Oral Abstracts
HIV Drug Resistance: Mechanisms and Impact on Response to New Agents
Wednesday, 10 am - 12:30 pm
Room: Lecture Hall

Moderators:

  Carlos Perno
  Univ of Tor Vergata, Rome, Italy

  Ronald Swanstrom
  Univ of North Carolina at Chapel Hill, US

10:00 am 152	Molecular Mechanism of Tenofovir, Abacavir, and Lamivudine Resistance by the K70E Mutation in HIV-1 Reverse Transcriptase Nicolas Sluis-Cremer*, P Argoti Torres, J Grzybowski, U Parikh, and J Mellors Univ of Pittsburgh, PA, US
10:15 am 153	Clonal Analysis of HIV-1 Quasi-species Enables Unambiguous Identification of the Genetic Determinants of Various Phenotypic Properties of the Envelope Proteins Jonathan Toma*, W Huang, T Wrin, S Fransen, J Whitcomb, and C Petropoulos Monogram Biosci, South San Francisco, CA, US
10:30 am 154	Effect of Baseline Resistance on the Virologic Response to a Novel NNRTI, TMC125, in Patients with Extensive NNRTI and PI Resistance: Analysis of Study TMC125-C223 Johan Vingerhoets*¹, M Peeters¹, C Corbett¹, K Iveson², K Vandermeulen¹, R Keen², B Woodfall¹, and M P De Béthune¹ ¹Tibotec, Mechelen, Belgium and ²Tibotec, Yardley, PA, US
10:45 am 155	Distinct Patterns of Sequence Variation in HIV-1 pro and pol in Chronically Infected ART-naïve Individuals Frank Maldarelli*¹, M Kearney¹, S Palmer¹, S Thawani¹, J Mican², D Rock², C Rehm², J Mellors³, and J Coffin¹ ¹NCI, Frederick, MD, US; ²NIAID, NIH, DHHS, Bethesda, MD, US; and ³Univ of Pittsburgh, PA, US
11:00 am 156	Viral Resistance to PA-457, a Novel Inhibitor of HIV-1 Maturation Catherine Adamson*¹, K Salzwedel², A Castillo², R Goila-Gaur¹, S Ablan¹, J Doto², J Doto, F Li², D Martin², C Wild², and E Freed¹ ¹HIV Drug Resistance Prgm, NCI, Frederick, MD, US and ²Panacos Pharma, Gaithersburg, MD, US
11:15 am 157	Effect of Baseline Susceptibility and On-treatment Mutations on TMC114 and Control PI Efficacy: Preliminary Analysis of Data from PI-experienced Patients from POWER 1 and POWER 2 Sandra De Meyer*¹, A Hill², I De Baere¹, L Rimsky¹, H Azijn¹, B Van Baelen¹, E De Paepe¹, T Vangeneugden¹, E Lefebvre³, and M P De Béthune¹ ¹Tibotec BVBA, Mechelen, Belgium; ²Univ of Liverpool, UK; and ³Tibotec, Yardley, PA, US
11:30 am 158LB	in vitro Characterization of HIV Isolated from Patients Treated with the Entry Inhibitor TNX-355 Thomas Duensing*, M Fung, S Lewis, and S Weinheimer Tanox, Inc, Houston, TX, US
11:45 am 159LB	Potent Antiretroviral Effect of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus Beatriz Grinsztejn*¹, B Y Nguyen², C Katlama³, J Gatell⁴, A Lazzarin⁵, D Vittecoq⁶, C Gonzalez⁷, J Chen², R Isaacs², and the Protocol 005 Study Team ¹Evandro Chagas Clinical Research Institute/Oswaldo Cruz Foundation, Rio de Janeiro, Brazil; ²Merck, West Point, PA, US; ³Hosp Pitié-Salpétrière, Paris, France; ⁴Univ of Barcelona, Spain; ⁵San Raffaele Sci Inst, Milan, Italy; ⁶Hosp Paul Borusse, Villejuif, France; and ⁷New York Univ Sch of Med, NY, US
12:00 pm 160LB	The HIV Integrase Inhibitor GS-9137 (JTK-303) Exhibits Potent Antiviral Activity in Treatment-naïve and Experienced Patients Edwin DeJesus*¹, D Berger², M Markowitz³, C Cohen⁴, T Hawkins⁵, P Ruane⁶, R Elion⁷, C Farthing⁸, A Cheng⁹, B Kearney⁹, and 183-0101 Study Team ¹Orlando Immunology Ctr, FL, US; ²Northstar Med Ctr, Chicago, IL, US; ³Aaron Diamond AIDS Res Ctr, Rockefeller Univ, New York, NY, US; ⁴Community Res Initiative of New England, Boston, MA, US; ⁵Southwest CARE, Santa Fe, NM, US; ⁶Light Source Med, Los Angeles, CA, US; ⁷CARE-ID, Washington DC, US; ⁸AIDS Hlthcare Fndn Res Ctr, Beverly Hills, CA, US; and ⁹Gilead Sci, Foster City, CA, US
12:15 pm 161LB	Late Virologic Breakthrough in Treatment-naive Patients on a Regimen of Combivir + Vicriviroc Wayne Greaves*¹, R Landovitz¹, G Fatkenheuer², C Hoffmann³, F Antunes⁴, J Angel⁵, N Boparai¹, D Knepp¹, A Keung¹, and L Dunkle¹ ¹Schering-Plough Res Inst, Kenilworth, NJ, US; ²Univ of Cologne, Germany; ³Univ of Kiel, Germany; ⁴Hosp Santa Maria, Lisbon, Portugal; and ⁵Ottawa Hosp, Canada